Physician profile
Daniel Witheiler
NPI 1023083482
$5,643.19
in general payments reported to CMS, 2019-2025
30 companies · $805 in 2025
The $805 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $868 · 2020: $146 · 2021: $517 · 2022: $1,101 · 2023: $1,053 · 2024: $1,153 · 2025: $805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,011.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,369.77 | 2019-2025 | Skyrizi, Rinvoq |
| Lilly USA, LLC | $623.08 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Genzyme Corporation | $561.82 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $491.63 | 2023-2025 | Zoryve |
| Janssen Biotech, INC. | $317.28 | 2021-2024 | Tremfya |
| Sun Pharmaceutical Industries INC. | $270.19 | 2019-2025 | Winlevi, Odomzo, Blu-U |
| E.R. Squibb & Sons, L.L.C. | $248.33 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $210.85 | 2021-2024 | Dupixent |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $163.04 | 2019-2024 | Siliq |
| Ucb, INC. | $139.99 | 2023-2025 | Bimzelx, Cimzia |
| Amgen INC. | $138.49 | 2020-2024 | Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $123.09 | 2023 | Spevigo |
| Leo Pharma INC. | $109.95 | 2019-2025 | Adbry, Anzupgo |
| Mayne Pharma Commercial LLC | $108.75 | 2019-2024 | |
| Galderma Laboratories, L.P. | $108.66 | 2019-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $94.92 | 2021-2022 | |
| Genentech USA, INC. | $87.69 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $80.08 | 2019-2025 | |
| Janssen Scientific Affairs, LLC | $70.38 | 2022 | |
| Epi Health, LLC | $57.24 | 2020-2022 | |
| Botanix Sb INC | $46.62 | 2025 | Sofdra |
| Dusa Pharmaceuticals, INC. | $38.22 | 2019 | |
| Incyte Corporation | $37.31 | 2021-2022 | |
| Pfizer INC. | $35.56 | 2021-2023 | |
| Merz North America, INC. | $24.91 | 2019 | |
| Organogenesis INC. | $22.28 | 2023 | Puraply |
| Allergan, INC. | $18.91 | 2022 | |
| Celgene Corporation | $16.87 | 2019 | |
| Journey Medical Corporation | $14.14 | 2022 | |
| Dermavant Sciences, INC. | $13.14 | 2024 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Witheiler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.